Companies / Travere Therapeutics, Inc.
Travere Therapeutics, Inc.
Nasdaq: TVTXCIK 1438533SAN DIEGO, CA
Financials · FY2025
Ownership
94.3M shares outstanding · as of Jul 30, 2026
Ownership
| Insiders | 1.27% | 1,192,519 |
| 10%+ / strategic | 19.72% | 18,587,418 |
| Institutions | 87.50% | 82,477,341 |
| Public float | 0.00% | 0 |
Reported holdings exceed shares outstanding — public float shown as 0; some positions may overlap or lag.
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 10
View all →| Insider | % of shares | Shares |
|---|---|---|
Dube Eric MCEOCHIEF EXECUTIVE OFFICER · Director | 0.46% | 432,886 |
Heerma PeterCHIEF COMMERCIAL OFFICER | 0.14% | 131,823 |
Cline Christopher R.CHIEF FINANCIAL OFFICER | 0.12% | 111,226 |
Rote William E.Chief Research Officer | 0.12% | 109,087 |
Inrig JulaCHIEF MEDICAL OFFICER | 0.11% | 105,706 |
Reed Elizabeth EChief Legal Officer and GC | 0.11% | 105,211 |
Lyons Gary aDirector | 0.07% | 61,500 |
Coughlin TimothyDirector | 0.06% | 56,250 |
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER | 0.05% | 49,080 |
Williams Brinkley RuthDirector | 0.03% | 29,750 |
Institutional holders 284
View all →| Holder | Value | % of shares |
|---|---|---|
| $455.65M | 8.51% | |
| $367.50M | 10.20% | |
| $339.25M | 12.11% | |
| $241.80M | 4.52% | |
| $241.08M | 6.69% | |
| $144.19M | 4.00% | |
| $143.82M | 3.99% | |
| $123.08M | 4.39% | |
| $84.46M | 2.34% | |
| $71.38M | 1.98% |
Activity
InsidersInstitutions
What insiders are doing in this stock (Form 4).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Feb 3, 2026 | Dube Eric M CEO | Sell | Common Stock | $2.13M | -66K -12.47% | 466,521 0.49% of shares | medium |
| Feb 20, 2026 | Dube Eric M CEO | Sell | Common Stock | $1.81M | -60K -12.17% | 432,886 0.46% of shares | medium |
| Jan 27, 2026 | Dube Eric M CEO | Sell | Common Stock | $1.56M | -52K -11.01% | 419,173 0.44% of shares | medium |
| Apr 14, 2026 | Reed Elizabeth E Executive | Sell | Common Stock | $1.54M | -38K -23.93% | 119,211 0.13% of shares | medium |
| Feb 3, 2026 | Dube Eric M CEO | Sell | Common Stock | $1.10M | -34K -7.21% | 432,886 0.46% of shares | medium |
| Feb 20, 2026 | Dube Eric M CEO | Exercise | Common Stock | $927.6K | +60K +13.86% | 492,886 0.52% of shares | low |
| May 4, 2026 | Reed Elizabeth E Executive | Sell | Common Stock | $900.0K | -20K -15.97% | 105,211 0.11% of shares | medium |
| Jan 27, 2026 | Dube Eric M CEO | Exercise | Common Stock | $801.8K | +52K +12.37% | 471,038 0.50% of shares | low |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| State Street Corporation | Passive13G | — |
| Vanguard Group Inc | Passive13G/A | — |
| Perceptive Advisors LLC | Passive13G/A | — |
| Macquarie Group Limited | Passive13G/A | — |
| Armistice Capital, LLC | Passive13G/A | — |
| Fmr LLC | Passive13G | — |
| State Street Corporation | Passive13G | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| TVTX | — | 89422G107 |